Yi-Xuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yi-Xuan Zhang has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Meng-Yue Zhang
School of Life Science and Biopharmaceutics
29 shared publicationsTian-Yuan Zhang
School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
17 shared publicationsYing-Ying Wu
School of Life Science and Biopharmaceutics
16 shared publicationsJuan Cheng
13 shared publicationsCai-Yun Wang
School of Life Science and Biopharmaceutics
5 shared publications- Meng-Yue Zhang
School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
5 shared publications
Latest Publications
- Open Access
Development and Preliminary Mechanistic Evaluation of a Novel Liposomal QS-21 and CpG ODNs Adjuvant System for Enhancing Vaccine Immunogenicity
Developing potent adjuvants is critical for enhancing vaccine efficacy, particularly for subunit antigens. Background/Objectives: This study evaluates a novel composite adjuvant system combining liposomal QS-21 and CpG ODNs to enhance vaccine-induced immunogenicity, particularly Th1-type cellular immunity. Methods: To mitigate QS-21’s hemolytic toxicity and ensure precision delivery, a stable liposomal formulation was developed. Mice models were established using varicella-zoster virus (VZV) glycoprotein E (gE) or ovalbumin (OVA) as antigens to evaluate humoral and cellular immune responses. Results: Immunization with gE protein formulated with this novel adjuvant synergistically triggered robust immune responses, outperforming single adjuvants and the combination of QS-21/MPL. Across broad dose ranges, it induced higher Th1-type cellular immunity and comparable humoral immunity relative to AS01B. Mechanistic studies revealed that the adjuvant significantly enhances the recruitment of dendritic cells (DCs), monocytes, and neutrophils to draining lymph nodes (dLNs) while upregulating co-stimulatory molecules CD40 and CD86 on DCs. Furthermore, the formulation triggered robust, transient increases in Th1-associated cytokines (IFN-γ, IL-12) and chemokines (CXCL9, CXCL10) across the injection site, serum, and dLNs. Conclusions: These findings indicate that the liposomal QS-21 and CpG ODNs system is a highly effective platform for promoting robust Th1-biased immunity, offering a promising adjuvant candidate and a solid experimental foundation for developing next-generation vaccines requiring potent cellular immunity.
Open AccessDevelopment and Preliminary Mechanistic Evaluation of a Novel Liposomal QS-21 and CpG ODNs Adjuvant System for Enhancing Vaccine Immunogenicity
Developing potent adjuvants is critical for enhancing vaccine efficacy, particularly for subunit antigens. Background/Objectives: This study evaluates a novel composite adjuvant system combining liposomal QS-21 and CpG ODNs to enhance vaccine-induced immunogenicity, particularly Th1-type cellular immunity. Methods: To mitigate QS-21’s hemolytic toxicity and ensure precision delivery, a stable liposomal formulation was developed. Mice models were established using varicella-zoster virus (VZV) glycoprotein E (gE) or ovalbumin (OVA) as antigens to evaluate humoral and cellular immune responses. Results: Immunization with gE protein formulated with this novel adjuvant synergistically triggered robust immune responses, outperforming single adjuvants and the combination of QS-21/MPL. Across broad dose ranges, it induced higher Th1-type cellular immunity and comparable humoral immunity relative to AS01B. Mechanistic studies revealed that the adjuvant significantly enhances the recruitment of dendritic cells (DCs), monocytes, and neutrophils to draining lymph nodes (dLNs) while upregulating co-stimulatory molecules CD40 and CD86 on DCs. Furthermore, the formulation triggered robust, transient increases in Th1-associated cytokines (IFN-γ, IL-12) and chemokines (CXCL9, CXCL10) across the injection site, serum, and dLNs. Conclusions: These findings indicate that the liposomal QS-21 and CpG ODNs system is a highly effective platform for promoting robust Th1-biased immunity, offering a promising adjuvant candidate and a solid experimental foundation for developing next-generation vaccines requiring potent cellular immunity.
- Open Access
- 26 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 746
An Orally Deliverable, Food-Compatible Lyophilized Recombinant Whole-Cell Catalyst for Alcohol-Associated Liver Injury
Effective oral interventions for alcohol-induced metabolic stress and liver injury remain limited. Pre-absorptive gastrointestinal alcohol handling is gaining interest as a non-pharmacological strategy to reduce hepatic burden. In this study, we developed a formulation-integrated, food-compatible lyophilized recombinant whole-cell catalyst based on Escherichia coli Nissle 1917 engineered to express alcohol dehydrogenase and acetaldehyde dehydrogenase. Rather than focusing exclusively on strain-level genetic modification, the engineered cells were protected by lyophilization combined with a food-grade chitosan–alginate layer-by-layer coating, forming an artificial cell wall designed to enhance survivability during oral delivery. The formulation resisted simulated gastric acid, sodium taurocholate, and ethanol, retained enzymatic activity after storage, and demonstrated formulation stability. In alcohol-exposed mice, oral administration reduced blood ethanol and acetaldehyde levels, improved liver biochemical parameters, attenuated hepatic steatosis, and partially restored oxidative stress indicators. Integrated multi-omics analyses indicated coordinated gut-associated metabolic and inflammatory responses to alcohol and intervention, rather than a single dominant pathway. These findings provide hypothesis-generating evidence; causality remains to be established. Overall, this study demonstrates a proof-of-concept, food-compatible lyophilized recombinant whole-cell catalyst that integrates enzymatic function with formulation stability and gastrointestinal resilience, highlighting an applied, food-compatible microbial framework for exploring alcohol-related metabolic stress.
- 26 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (4) , 746
Open AccessAn Orally Deliverable, Food-Compatible Lyophilized Recombinant Whole-Cell Catalyst for Alcohol-Associated Liver Injury
Effective oral interventions for alcohol-induced metabolic stress and liver injury remain limited. Pre-absorptive gastrointestinal alcohol handling is gaining interest as a non-pharmacological strategy to reduce hepatic burden. In this study, we developed a formulation-integrated, food-compatible lyophilized recombinant whole-cell catalyst based on Escherichia coli Nissle 1917 engineered to express alcohol dehydrogenase and acetaldehyde dehydrogenase. Rather than focusing exclusively on strain-level genetic modification, the engineered cells were protected by lyophilization combined with a food-grade chitosan–alginate layer-by-layer coating, forming an artificial cell wall designed to enhance survivability during oral delivery. The formulation resisted simulated gastric acid, sodium taurocholate, and ethanol, retained enzymatic activity after storage, and demonstrated formulation stability. In alcohol-exposed mice, oral administration reduced blood ethanol and acetaldehyde levels, improved liver biochemical parameters, attenuated hepatic steatosis, and partially restored oxidative stress indicators. Integrated multi-omics analyses indicated coordinated gut-associated metabolic and inflammatory responses to alcohol and intervention, rather than a single dominant pathway. These findings provide hypothesis-generating evidence; causality remains to be established. Overall, this study demonstrates a proof-of-concept, food-compatible lyophilized recombinant whole-cell catalyst that integrates enzymatic function with formulation stability and gastrointestinal resilience, highlighting an applied, food-compatible microbial framework for exploring alcohol-related metabolic stress.
- Open Access
- 13 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (3) , 653
An Improved Method for Determining the Infection Titer of Replication-Competent Adeno-Associated Virus
Background/Objectives: Recombinant adeno-associated virus (rAAV) has become a leading vector in gene therapy. However, manufacturing limitations may result in replication-competent AAV (rcAAV) contamination of clinical rAAV products, posing safety risks. Rigorous testing is therefore essential, and the use of accurately calibrated rcAAV reference standard materials is critical for ensuring assay stability and reliability. A disadvantage of the widely used Tissue Culture Infectious Dose 50 (TCID50) assay is its high variability. This study introduces an optimized TCID50 assay for the precise quantification of infectious rcAAV particles. Methods: We developed a TCID50 assay tailored to rep2-based rcAAV, optimizing key aspects such as viral infection conditions, qPCR reaction systems, and standard curve preparation. We employed an innovative strategy to prepare the standard curve using serial dilutions of rcAAV in cell lysate, ensuring alignment with the test sample matrices. Results: The rcAAV-derived standard curve demonstrated exceptional linearity (R2 > 0.99), sensitivity (LOQ ≈ 38 copies), and reproducibility, enabling robust endpoint qPCR analysis. The optimized assay significantly improved the precision of the TCID50 assay, as an inter-assay coefficient of variation (CV) of 11.4% was achieved. Conclusions: This refined TCID50 assay is a reliable method for calibrating infectious titers of rcAAV reference standard materials, thereby enabling the standardization of rcAAV testing.
- 13 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (3) , 653
Open AccessAn Improved Method for Determining the Infection Titer of Replication-Competent Adeno-Associated Virus
Background/Objectives: Recombinant adeno-associated virus (rAAV) has become a leading vector in gene therapy. However, manufacturing limitations may result in replication-competent AAV (rcAAV) contamination of clinical rAAV products, posing safety risks. Rigorous testing is therefore essential, and the use of accurately calibrated rcAAV reference standard materials is critical for ensuring assay stability and reliability. A disadvantage of the widely used Tissue Culture Infectious Dose 50 (TCID50) assay is its high variability. This study introduces an optimized TCID50 assay for the precise quantification of infectious rcAAV particles. Methods: We developed a TCID50 assay tailored to rep2-based rcAAV, optimizing key aspects such as viral infection conditions, qPCR reaction systems, and standard curve preparation. We employed an innovative strategy to prepare the standard curve using serial dilutions of rcAAV in cell lysate, ensuring alignment with the test sample matrices. Results: The rcAAV-derived standard curve demonstrated exceptional linearity (R2 > 0.99), sensitivity (LOQ ≈ 38 copies), and reproducibility, enabling robust endpoint qPCR analysis. The optimized assay significantly improved the precision of the TCID50 assay, as an inter-assay coefficient of variation (CV) of 11.4% was achieved. Conclusions: This refined TCID50 assay is a reliable method for calibrating infectious titers of rcAAV reference standard materials, thereby enabling the standardization of rcAAV testing.
- 13 February 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 262, 115551
Enhanced brain targeting and improved Alzheimer's disease therapy via intranasal delivery of Ginsenoside F1-loaded mixed micelles
- 13 February 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 262, 115551
Enhanced brain targeting and improved Alzheimer's disease therapy via intranasal delivery of Ginsenoside F1-loaded mixed micelles
- Open Access
- 30 December 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (12) , e04878
Low‐Temperature Fabrication of Thymosin β4‐Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22rɑ2
Skin wound treatment is hindered by the poor penetration of large therapeutics and a lack of treatments that effectively regulate immune environments. While microneedles (MNs) can bypass the skin, they destabilize sensitive peptides, including thymosin β4 (Tβ4), whose immunomodulatory targets are not well understood, limiting their clinical use. This study introduces a novel fabrication method for Tβ4‐loaded soluble MNs at low temperatures using chitosan and sucrose, avoiding the denaturing conditions of traditional MN production. These MNs exhibit a uniform shape, high drug capacity (248.15 ± 1.37 µg/patch), quick dissolution within an hour, excellent biocompatibility, and significantly enhanced wound healing in mice. This study examines the mechanism by which Tβ4 accelerates wound healing, identifying the downregulated immune regulators Spp1, Vsig4, and IL22rɑ2 through RNA‐seq and DEG analysis. In vitro qPCR, western blot, and surface plasmon resonance (SPR) experiments demonstrate that Tβ4 specifically binds to the downregulated immune regulators Vsig4 (K D = 3.56 × 10 −6 m ) and IL22rɑ2 (K D = 9.69 × 10 −6 m ). This article explores how Tβ4 influences the wound immune microenvironment to aid healing, identifies its specific molecular targets, and moves beyond its general roles to offer new opportunities for drug development.
- 30 December 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (12) , e04878
Open AccessLow‐Temperature Fabrication of Thymosin β4‐Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22rɑ2
Skin wound treatment is hindered by the poor penetration of large therapeutics and a lack of treatments that effectively regulate immune environments. While microneedles (MNs) can bypass the skin, they destabilize sensitive peptides, including thymosin β4 (Tβ4), whose immunomodulatory targets are not well understood, limiting their clinical use. This study introduces a novel fabrication method for Tβ4‐loaded soluble MNs at low temperatures using chitosan and sucrose, avoiding the denaturing conditions of traditional MN production. These MNs exhibit a uniform shape, high drug capacity (248.15 ± 1.37 µg/patch), quick dissolution within an hour, excellent biocompatibility, and significantly enhanced wound healing in mice. This study examines the mechanism by which Tβ4 accelerates wound healing, identifying the downregulated immune regulators Spp1, Vsig4, and IL22rɑ2 through RNA‐seq and DEG analysis. In vitro qPCR, western blot, and surface plasmon resonance (SPR) experiments demonstrate that Tβ4 specifically binds to the downregulated immune regulators Vsig4 (K D = 3.56 × 10 −6 m ) and IL22rɑ2 (K D = 9.69 × 10 −6 m ). This article explores how Tβ4 influences the wound immune microenvironment to aid healing, identifies its specific molecular targets, and moves beyond its general roles to offer new opportunities for drug development.
- Open Access
- 10 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2812
Combination Therapy with Azithromycin and Clostridium butyricum Retains Anti-Diarrheal Efficacy but Partially Compromises Gut Microbiota Restoration Compared to Probiotics Monotherapy
Most probiotics require separate administration from antibiotics due to sensitivity issues. Clostridium butyricum, however, exhibits intrinsic resistance, making it a promising candidate for combined therapy against diarrhea. In this study, a diarrhea model was established in mice induced by Escherichia coli, followed by treatment with azithromycin (AZM), C. butyricum (RH2), or their combination (COM) to assess therapeutic efficacy. The results demonstrated that mice in RH2 and COM groups achieved full body weight recovery and significant alleviation of diarrhea, accompanied by normalized fecal E. coli loads, preserved tissue integrity, reduced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and elevated anti-inflammatory IL-10. In contrast, AZM treatment led to sex-specific disparities in weight recovery and E. coli loads, and both sexes experienced relapse-prone diarrhea. Furthermore, the AZM group displayed shortened colons, sustained inflammatory infiltration, epithelial damage, and elevated IL-1β and male-specific IL-6. Gut microbiota analysis revealed that the COM group retained beneficial genera (e.g., Parabacteroides, Blautia) from the AZM group while uniquely enriching Lachnospiraceae taxa (e.g., NK4A136_group, FCS020_group). Untargeted metabolomics demonstrated the COM group activated GABA/arginine pathways, enhancing anti-inflammatory and barrier functions, whereas azithromycin disrupted butyrate synthesis and steroid metabolism. These findings highlight the advantage of combining C. butyricum with azithromycin for intestinal protection.
- 10 December 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2812
Open AccessCombination Therapy with Azithromycin and Clostridium butyricum Retains Anti-Diarrheal Efficacy but Partially Compromises Gut Microbiota Restoration Compared to Probiotics Monotherapy
Most probiotics require separate administration from antibiotics due to sensitivity issues. Clostridium butyricum, however, exhibits intrinsic resistance, making it a promising candidate for combined therapy against diarrhea. In this study, a diarrhea model was established in mice induced by Escherichia coli, followed by treatment with azithromycin (AZM), C. butyricum (RH2), or their combination (COM) to assess therapeutic efficacy. The results demonstrated that mice in RH2 and COM groups achieved full body weight recovery and significant alleviation of diarrhea, accompanied by normalized fecal E. coli loads, preserved tissue integrity, reduced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and elevated anti-inflammatory IL-10. In contrast, AZM treatment led to sex-specific disparities in weight recovery and E. coli loads, and both sexes experienced relapse-prone diarrhea. Furthermore, the AZM group displayed shortened colons, sustained inflammatory infiltration, epithelial damage, and elevated IL-1β and male-specific IL-6. Gut microbiota analysis revealed that the COM group retained beneficial genera (e.g., Parabacteroides, Blautia) from the AZM group while uniquely enriching Lachnospiraceae taxa (e.g., NK4A136_group, FCS020_group). Untargeted metabolomics demonstrated the COM group activated GABA/arginine pathways, enhancing anti-inflammatory and barrier functions, whereas azithromycin disrupted butyrate synthesis and steroid metabolism. These findings highlight the advantage of combining C. butyricum with azithromycin for intestinal protection.
- Open Access
- 18 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (47) , 57711-57723
Discovery of New Angucyclin(on)e Derivatives and Their Genetic Architecture from Streptomyces sp. SYP-A7185 in the Rhizosphere Soil of Panax notoginseng
Strain SYP-A7185 was isolated from the rhizosphere soil of Panax notoginseng (Burk.) F. H. Chen, a medicinal plant in Wenshan District, Yunnan Province, China. Phylogenetic analysis indicated that strain SYP-A7185 exhibited a 99.78% similarity to Streptomyces rosealbus YIM 31634T. The complete genome of Streptomyces sp. SYP-A7185 harbored 26 putative biosynthetic gene clusters (BGCs) associated with secondary metabolite biosynthesis. By integrating genomic strategies and metabolites analysis, four new nonclassical angucyclin(on)e derivatives (1, 3, 4, and 7) and three known compounds (2, 5, and 6) were identified. Characterization of BGC-14 as the angucyclin(on)es (Agn) biosynthetic gene cluster, together with the reconstruction of the biosynthetic pathway, highlighted the significant involvement of oxidoreductases AgnO1–AgnO7 in synthesizing compounds 1–7. Strikingly, this particular angucyclin(on)e biosynthetic gene cluster exhibited an uncommon occurrence of six glycosyltransferases AgnGT1–AgnGT6. The identification of these biosynthetic elements significantly expands the genetic resource available for angucyclin(on)e biosynthesis, providing valuable tools for targeted genetic manipulation and pathway engineering. Furthermore, cytotoxicity and antimicrobial assays showed that compounds 1–3 exhibited moderate antiproliferative effects, while compound 4 demonstrated moderate antimicrobial activity against Staphylococcus aureus and Klebsiella pneumoniae. The experimental findings underscore the diversity of angucyclin(on)e derivatives and their biological properties, providing valuable insights for future research and exploration.
- 18 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (47) , 57711-57723
Open AccessDiscovery of New Angucyclin(on)e Derivatives and Their Genetic Architecture from Streptomyces sp. SYP-A7185 in the Rhizosphere Soil of Panax notoginseng
Strain SYP-A7185 was isolated from the rhizosphere soil of Panax notoginseng (Burk.) F. H. Chen, a medicinal plant in Wenshan District, Yunnan Province, China. Phylogenetic analysis indicated that strain SYP-A7185 exhibited a 99.78% similarity to Streptomyces rosealbus YIM 31634T. The complete genome of Streptomyces sp. SYP-A7185 harbored 26 putative biosynthetic gene clusters (BGCs) associated with secondary metabolite biosynthesis. By integrating genomic strategies and metabolites analysis, four new nonclassical angucyclin(on)e derivatives (1, 3, 4, and 7) and three known compounds (2, 5, and 6) were identified. Characterization of BGC-14 as the angucyclin(on)es (Agn) biosynthetic gene cluster, together with the reconstruction of the biosynthetic pathway, highlighted the significant involvement of oxidoreductases AgnO1–AgnO7 in synthesizing compounds 1–7. Strikingly, this particular angucyclin(on)e biosynthetic gene cluster exhibited an uncommon occurrence of six glycosyltransferases AgnGT1–AgnGT6. The identification of these biosynthetic elements significantly expands the genetic resource available for angucyclin(on)e biosynthesis, providing valuable tools for targeted genetic manipulation and pathway engineering. Furthermore, cytotoxicity and antimicrobial assays showed that compounds 1–3 exhibited moderate antiproliferative effects, while compound 4 demonstrated moderate antimicrobial activity against Staphylococcus aureus and Klebsiella pneumoniae. The experimental findings underscore the diversity of angucyclin(on)e derivatives and their biological properties, providing valuable insights for future research and exploration.
- Open Access
- 1 November 2025
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 14 (11)
Lactiplantibacillus plantarum and quercetin synergistically ameliorate hyperuricemia through targeting multiple pathways
Hyperuricemia is a prevalent metabolic disorder resulting from dysregulation of purine metabolism, often accompanied by inflammation. It is characterized by an abnormal elevation in uric acid levels. In our investigation, the combined treatment with Lactobacillus plantarum DY1 and quercetin suppressed the activity of xanthine oxidase and adenosine deaminase, decreased the levels of uric acid, TNF-α and IL-β, downregulated gene expression of URAT1 and GLUT9, and upregulated OAT1 and ABCG2. The combination increased the abundance of Lactobacillus and decreased the abundance of norank_f_norank_o_Clostridia_UCG-014 and Roseburia. Metabolomics analysis revealed that the combination of probiotics and quercetin exhibited distinct metabolic pathways compared to their individual administrations. When compared to probiotics alone, the combination led to alterations in glutathione metabolism (oxidized glutathione and glutathione) as well as sphingolipid metabolism (sphingosine and sphinganine). When compared to quercetin alone, the combination resulted in variations in tryptophan metabolism (indole-3-acetamide, 5-hydroxy-L-tryptophan, indoleacetaldehyde, 3-(3-Indolyl)-2-oxopropanoic acid, 3-indoleacetic acid and 3-methylindole) along with purine metabolism (UA, xanthosine, cAMP, ADP and adenosine monophosphate). The subsequent fecal microbiota transplantation proved that the effect of the combination on reducing uric acid levels was mediated by the gut microbiota. Therefore, this new combination can be considered a promising adjuvant therapy capable of synergistically alleviating hyperuricemia.
- 1 November 2025
- Published by Tsinghua University Press in Food Science and Human Wellness
- Vol. 14 (11)
Open AccessLactiplantibacillus plantarum and quercetin synergistically ameliorate hyperuricemia through targeting multiple pathways
Hyperuricemia is a prevalent metabolic disorder resulting from dysregulation of purine metabolism, often accompanied by inflammation. It is characterized by an abnormal elevation in uric acid levels. In our investigation, the combined treatment with Lactobacillus plantarum DY1 and quercetin suppressed the activity of xanthine oxidase and adenosine deaminase, decreased the levels of uric acid, TNF-α and IL-β, downregulated gene expression of URAT1 and GLUT9, and upregulated OAT1 and ABCG2. The combination increased the abundance of Lactobacillus and decreased the abundance of norank_f_norank_o_Clostridia_UCG-014 and Roseburia. Metabolomics analysis revealed that the combination of probiotics and quercetin exhibited distinct metabolic pathways compared to their individual administrations. When compared to probiotics alone, the combination led to alterations in glutathione metabolism (oxidized glutathione and glutathione) as well as sphingolipid metabolism (sphingosine and sphinganine). When compared to quercetin alone, the combination resulted in variations in tryptophan metabolism (indole-3-acetamide, 5-hydroxy-L-tryptophan, indoleacetaldehyde, 3-(3-Indolyl)-2-oxopropanoic acid, 3-indoleacetic acid and 3-methylindole) along with purine metabolism (UA, xanthosine, cAMP, ADP and adenosine monophosphate). The subsequent fecal microbiota transplantation proved that the effect of the combination on reducing uric acid levels was mediated by the gut microbiota. Therefore, this new combination can be considered a promising adjuvant therapy capable of synergistically alleviating hyperuricemia.
- Open Access
- 10 June 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (6) , 1347
Survival and Morphological Changes of Clostridium butyricum Spores Co-Exposed to Antibiotics and Simulated Gastrointestinal Fluids: Implications for Antibiotic Stewardship
Probiotics are often advised to be taken separately from antibiotics due to their sensitivity to antibiotic activity and gastrointestinal (GI) stress. However, Clostridium butyricum spores, as next-generation probiotics, may withstand concurrent use with antibiotics due to their unique structural adaptations. This study systematically evaluated the survival rates and morphological changes of C. butyricum spores exposed to 10 clinically relevant antibiotics in simulated gastric/intestinal fluids, exploring their feasibility for co-administration with antibiotics. Survival rates of C. butyricum spores were tested against 10 antibiotics across four classes (β-lactams, macrolides, aminoglycosides, and tetracyclines) in simulated GI fluids. Time–kill curves analyzed spore survival over 0–4 h, while scanning electron microscopy (SEM) observed spore wall integrity and morphological changes under different conditions. The spore survival rates remained >89% in intestinal fluid and >60% in gastric fluid across all antibiotics. SEM revealed gastric acid and proteolysis increased spore wall fragmentation, reducing resistance, whereas the intestinal environment preserved spore integrity. This study was the first to demonstrate that C. butyricum spores can survive simultaneous exposure to antibiotics in the gastrointestinal tract, challenging traditional probiotic usage guidelines. The findings support their co-administration with antibiotics to simplify dosing regimens and improve medication adherence. Such an approach advances antimicrobial stewardship by optimizing therapeutic strategies for antibiotic–probiotic combinations.
- 10 June 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (6) , 1347
Open AccessSurvival and Morphological Changes of Clostridium butyricum Spores Co-Exposed to Antibiotics and Simulated Gastrointestinal Fluids: Implications for Antibiotic Stewardship
Probiotics are often advised to be taken separately from antibiotics due to their sensitivity to antibiotic activity and gastrointestinal (GI) stress. However, Clostridium butyricum spores, as next-generation probiotics, may withstand concurrent use with antibiotics due to their unique structural adaptations. This study systematically evaluated the survival rates and morphological changes of C. butyricum spores exposed to 10 clinically relevant antibiotics in simulated gastric/intestinal fluids, exploring their feasibility for co-administration with antibiotics. Survival rates of C. butyricum spores were tested against 10 antibiotics across four classes (β-lactams, macrolides, aminoglycosides, and tetracyclines) in simulated GI fluids. Time–kill curves analyzed spore survival over 0–4 h, while scanning electron microscopy (SEM) observed spore wall integrity and morphological changes under different conditions. The spore survival rates remained >89% in intestinal fluid and >60% in gastric fluid across all antibiotics. SEM revealed gastric acid and proteolysis increased spore wall fragmentation, reducing resistance, whereas the intestinal environment preserved spore integrity. This study was the first to demonstrate that C. butyricum spores can survive simultaneous exposure to antibiotics in the gastrointestinal tract, challenging traditional probiotic usage guidelines. The findings support their co-administration with antibiotics to simplify dosing regimens and improve medication adherence. Such an approach advances antimicrobial stewardship by optimizing therapeutic strategies for antibiotic–probiotic combinations.